67 related articles for article (PubMed ID: 20720576)
1. Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector.
Choi SH; Lee HC
Gene Ther; 2011 Feb; 18(2):155-63. PubMed ID: 20720576
[TBL] [Abstract][Full Text] [Related]
2. DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes.
Riedel MJ; Gaddy DF; Asadi A; Robbins PD; Kieffer TJ
Gene Ther; 2010 Feb; 17(2):171-80. PubMed ID: 19865180
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.
Lee YS; Shin S; Shigihara T; Hahm E; Liu MJ; Han J; Yoon JW; Jun HS
Diabetes; 2007 Jun; 56(6):1671-9. PubMed ID: 17369525
[TBL] [Abstract][Full Text] [Related]
4. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice.
Kumar M; Hunag Y; Glinka Y; Prud'homme GJ; Wang Q
Gene Ther; 2007 Jan; 14(2):162-72. PubMed ID: 16943856
[TBL] [Abstract][Full Text] [Related]
6. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes.
Soltani N; Kumar M; Glinka Y; Prud'homme GJ; Wang Q
Gene Ther; 2007 Jun; 14(12):981-8. PubMed ID: 17410180
[TBL] [Abstract][Full Text] [Related]
7. In vivo expression of HGF/NK1 and GLP-1 From dsAAV vectors enhances pancreatic ß-cell proliferation and improves pathology in the db/db mouse model of diabetes.
Gaddy DF; Riedel MJ; Pejawar-Gaddy S; Kieffer TJ; Robbins PD
Diabetes; 2010 Dec; 59(12):3108-16. PubMed ID: 20841608
[TBL] [Abstract][Full Text] [Related]
8. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.
Riedel MJ; Lee CW; Kieffer TJ
Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E936-44. PubMed ID: 19190262
[TBL] [Abstract][Full Text] [Related]
9. Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes.
Jean M; Alameh M; Buschmann MD; Merzouki A
Gene Ther; 2011 Aug; 18(8):807-16. PubMed ID: 21412280
[TBL] [Abstract][Full Text] [Related]
10. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
11. A single injection of double-stranded adeno-associated viral vector expressing GH normalizes growth in GH-deficient mice.
Sagazio A; Xiao X; Wang Z; Martari M; Salvatori R
J Endocrinol; 2008 Jan; 196(1):79-88. PubMed ID: 18180319
[TBL] [Abstract][Full Text] [Related]
12. Double-strand adeno-associated virus-mediated exendin-4 expression in salivary glands is efficient in a diabetic rat model.
Wang J; Wang F; Xu J; Ding S; Guo Y
Diabetes Res Clin Pract; 2014 Mar; 103(3):466-73. PubMed ID: 24438876
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
14. dsAAV8-mediated gene transfer and β-cell expression of IL-4 and β-cell growth factors are capable of reversing early-onset diabetes in NOD mice.
Gaddy DF; Riedel MJ; Bertera S; Kieffer TJ; Robbins PD
Gene Ther; 2012 Aug; 19(8):791-9. PubMed ID: 22089495
[TBL] [Abstract][Full Text] [Related]
15. Defective adenoassociated viral-mediated transfection of insulin gene by direct injection into liver parenchyma decreases blood glucose of diabetic mice.
Sugiyama A; Hattori S; Tanaka S; Isoda F; Kleopoulos S; Rosenfeld M; Kaplitt M; Sekihara H; Mobbs C
Horm Metab Res; 1997 Dec; 29(12):599-603. PubMed ID: 9497894
[TBL] [Abstract][Full Text] [Related]
16. Effect of polyethylenimine on recombinant adeno-associated virus mediated insulin gene therapy.
Hsu PY; Yang YW
J Gene Med; 2005 Oct; 7(10):1311-21. PubMed ID: 15906397
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
Nauck MA; Holst JJ; Willms B; Schmiegel W
Exp Clin Endocrinol Diabetes; 1997; 105(4):187-95. PubMed ID: 9285204
[TBL] [Abstract][Full Text] [Related]
20. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
